Related Experiment Video
Updated: Aug 9, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I)
1Mayo Clinic, Rochester, Minnesota 55905.
Abstract:
Amiodarone represents an important new approach in the treatment of serious cardiac rhythm disturbances and is associated with significant pulmonary toxicity in approximately 5 to 10 percent of patients. The recognition of APT in patients receiving the drug early in the course of the disease will likely preclude the development of a permanent loss of pulmonary function in these patients. It is important for the clinician to individualize both the diagnostic and therapeutic approach to the patient receiving amiodarone who is thought to have pulmonary toxicity secondary to the drug. Several diagnostic and therapeutic decisions are available, and it is important to constantly reevaluate the risk-benefit ratios of the decision making process. Future studies may improve insight into the assessment of APT and may permit the clinician to diagnose this toxicity at an earlier and potentially more reversible stage of the disease process.
Insights
Early recognition of amiodarone pulmonary toxicity (APT) in patients is crucial. Prompt diagnosis and individualized treatment can prevent permanent lung damage from this cardiac drug.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Amiodarone is a key treatment for cardiac arrhythmias.
- A significant percentage of patients (5-10%) develop amiodarone pulmonary toxicity (APT).
- APT can lead to irreversible pulmonary function loss.
Purpose of the Study:
- To emphasize the importance of early APT recognition.
- To guide clinicians in diagnosing and managing amiodarone-induced lung injury.
- To highlight the need for individualized risk-benefit assessment.
Main Methods:
- Review of clinical data and treatment protocols for amiodarone use.
- Analysis of diagnostic strategies for amiodarone pulmonary toxicity.
- Evaluation of therapeutic interventions and their outcomes.
Main Results:
- Early identification of APT is linked to better patient outcomes.
- Individualized diagnostic and therapeutic approaches are essential.
- Ongoing risk-benefit reevaluation is critical for patient management.
Conclusions:
- Timely diagnosis of amiodarone pulmonary toxicity can prevent permanent lung damage.
- Personalized management strategies are vital for patients on amiodarone.
- Further research is needed to enhance early detection and reversibility of APT.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Myocarditis I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Pulmonary Edema II: Pathophysiology

